InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Neumora Therapeutics, Inc.

NMRA Clue Score40
United States Fiscal year ends December CIK 0001885522
$0.48 -0.85% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $0.48 −96.02% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 14 Sep 2023. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2022Operating income−135.9Net income−130.9EPS, diluted−4.81Fiscal year 2023Operating income−252.1Net income−235.9EPS, diluted−3.63Fiscal year 2024Operating income−263.5Net income−243.8EPS, diluted−1.53Fiscal year 2025Operating income−241.2Net income−236.9EPS, diluted−1.45
FY2022FY2023FY2024FY2025
Operating income −135.9 −252.1 −263.5 −241.2
Net income −130.9 −235.9 −243.8 −236.9
Growth
EPS, diluted −4.81 −3.63 −1.53 −1.45

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2022Operating cash flow−114.9Capital expenditure−0.5Free cash flow−115.4Fiscal year 2023Operating cash flow−163.3Capital expenditure−0.1Free cash flow−163.4Fiscal year 2024Operating cash flow−182.9Fiscal year 2025Operating cash flow−206.4
FY2022FY2023FY2024FY2025
Operating cash flow −114.9 −163.3 −182.9 −206.4
Capital expenditure −0.5 −0.1 n/a n/a
Free cash flow −115.4 −163.4 n/a n/a
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2022Cash240.9Shareholders’ equity−446.9Fiscal year 2023Cash374.0Shareholders’ equity469.1Fiscal year 2024Cash142.1Total debt0.0Net cash (debt)142.1Shareholders’ equity287.1Debt to equity0.00Fiscal year 2025Cash182.5Total debt114.5Net cash (debt)68.0Shareholders’ equity103.9Debt to equity1.10
FY2022FY2023FY2024FY2025
Cash 240.9 374.0 142.1 182.5
Total debt n/a n/a 0.0 114.5
Net cash (debt) n/a n/a 142.1 68.0
Shareholders’ equity −446.9 469.1 287.1 103.9
Debt to equity n/a n/a 0.00 1.10

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2022 31 Dec 2022 FY2023† 31 Dec 2023 FY2024† 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
91.7 142.7 200.9 176.1
31.1 45.5 62.5 60.1
−135.9 −252.1 −263.5 −241.2
Growth
−130.9 −235.7 −243.6 −236.8
n/a 0.3 0.2 0.1
−130.9 −235.9 −243.8 −236.9
Growth
Per share
−4.81 −3.63 −1.53 −1.45
−4.81 −3.63 −1.53 −1.45
Growth
27.2 65.0 159.4 163.4
27.2 65.0 159.4 163.4
Growth +139.0% +145.1% +2.5%

† The diluted share count jumps at 2023 and 2024, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 4 of 4 years on file.